Quicksilver II: Rectal cancer study after surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This pilot study tests a new approach for people with Stage II or III rectal cancer that was successfully removed with clear margins. It aims to see if a less intensive treatment plan can work well for patients whose tumors don't have high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years of age or older.
- You must be able to understand and sign the consent form.
- You need a diagnosis of Stage II or III rectal cancer that an MRI shows was completely removed (clear margins).
- Your tumor should not have high-risk features that would normally require treatment before surgery (like needing a permanent colostomy, T4 tumor, or certain enlarged lymph nodes).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a period of active surveillance (watching closely) and chemotherapy before surgery can improve outcomes for people with stage II–III rectal cancer. You would also receive standard chemo-radiation if you qualify, then proceed to surgery.
This trial tests a short course of radiation therapy combined with chemotherapy for people with stage II or III rectal cancer. It’s designed to see whether this approach is safe and effective before or around cancer surgery.
This Phase 2 trial compares a pre-surgery (neoadjuvant) treatment plan versus the standard plan for people with stage II–III rectal cancer. The goal is to see which approach works better and is safe before surgery.
This study looks at whether it’s practical and safe to treat certain rectal cancers without surgery. You may be offered non-surgical (“neoadjuvant”) treatment and close follow-up to see how well it works in a rural setting.
This Phase 2 study tests whether a shorter course of radiation, combined with chemotherapy (CAPOX) and an immunotherapy drug (tislelizumab), can control middle and low rectal cancer. It may also help people who strongly want to keep their anus, if the cancer and overall health fit the study rules.
This trial compares two treatment approaches for stage II (T3) rectal cancer: chemoradiation before surgery versus a total neoadjuvant therapy approach (chemotherapy and radiation) before surgery. It aims to find which is more effective and safer.
Hear when a new Stage II Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.